According to Aipu Co., Ltd. announced that the company set up a wholly-owned subsidiary, Aipu Life Technology, to transfer 100% of Noah Shengnuo Biotech's shares held by Noah Shengnuo Europe for 450 million yuan, and traded in two installments. 80% of the shares were transferred for the first time, and the remaining 20% of the shares were transferred for the second time after the performance commitment period expired. On June 22, 2026, the two sides signed the transfer agreement and supplementary agreement. On August 13, Aipu Life Technology completed the delivery of the first transaction and obtained 80% of the target company's shares. After the transaction is completed, there may be risks such as poor coordination between the two parties, and the company will promptly disclose the progress.

According to Aipu Co., Ltd. announced that the company set up a wholly-owned subsidiary, Aipu Life Technology, to transfer 100% of Noah Shengnuo Biotech's shares held by Noah Shengnuo Europe for 450 million yuan, and traded in two installments. 80% of the shares were transferred for the first time, and the remaining 20% of the shares were transferred for the second time after the performance commitment period expired. On June 22, 2026, the two sides signed the transfer agreement and supplementary agreement. On August 13, Aipu Life Technology completed the delivery of the first transaction and obtained 80% of the target company's shares. After the transaction is completed, there may be risks such as poor coordination between the two parties, and the company will promptly disclose the progress.